← Back to Search

Other

Expiratory muscle strength therapy (EMST150, Aspire LLC) for Myopathy

N/A
Waitlist Available
Led By Gerald Pfeffer, MD, PhD
Research Sponsored by University of Calgary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change in score from week 0 to week 5; change in score from week 0 to week 15; change in score from week 5 to week 15.
Awards & highlights

Study Summary

This trial looks at whether a muscle training programme can help people with OPMD to improve their swallowing, breathing, oral intake and quality of life, as well as their cough function.

Eligible Conditions
  • Myopathy
  • Muscular Dystrophy
  • Oculopharyngeal Muscular Dystrophy

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change in score from week 0 to week 5; change in score from week 0 to week 15; change in score from week 5 to week 15.
This trial's timeline: 3 weeks for screening, Varies for treatment, and change in score from week 0 to week 5; change in score from week 0 to week 15; change in score from week 5 to week 15. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
Biomarker analyses
Forced vital capacity (FVC)
Global Swallowing Function
+4 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: EMST therapyExperimental Treatment1 Intervention
Participants use the EMST device as per study protocol, set to 50% of the patient's maximal expiratory pressure, as measured by handheld manometer.
Group II: Sham EMST therapyPlacebo Group1 Intervention
Participants use a sham EMST device that has the spring removed as per study protocol, with no significant airflow resistance.

Find a Location

Who is running the clinical trial?

University of CalgaryLead Sponsor
792 Previous Clinical Trials
869,134 Total Patients Enrolled
Muscular Dystrophy CanadaOTHER
3 Previous Clinical Trials
147 Total Patients Enrolled
Gerald Pfeffer, MD, PhDPrincipal InvestigatorUniversity of Calgary

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Journal of Neurology, Neurosurgery & PsychiatryJournal
Electrophysiological Evaluation of Oropharyngeal Swallowing in Myotonic Dystrophy
Ertekin, C. 2001. “Electrophysiological Evaluation of Oropharyngeal Swallowing in Myotonic Dystrophy”. Journal of Neurology, Neurosurgery & Psychiatry. BMJ. doi:10.1136/jnnp.70.3.363.
NeuroRehabilitationJournal
Amyotrophic Lateral Sclerosis Survival Analysis: Swallowing and Non-oral Feeding
Luchesi, K.F., S. Kitamua, and L.F. Mourão. 2014. “Amyotrophic Lateral Sclerosis Survival Analysis: Swallowing and Non-oral Feeding”. Neurorehabilitation. IOS Press. doi:10.3233/nre-141149.
Amyotrophic Lateral SclerosisJournal
Prognostic Factors in ALS: A Critical Review
Chiò, Adriano, Giancarlo Logroscino, Orla Hardiman, Robert Swingler, Douglas Mitchell, Ettore Beghi, Bryan G. Traynor, and On Behalf of the Eurals Consortium. 2009. “Prognostic Factors in ALS: A Critical Review”. Amyotrophic Lateral Sclerosis. Informa UK Limited. doi:10.3109/17482960802566824.
Journal of Oral RehabilitationJournal
Oropharyngeal Dysphagia in Amyotrophic Lateral Sclerosis Alters Quality of Life
Paris, G., O. Martinaud, A. Petit, A. Cuvelier, D. Hannequin, P. Roppeneck, and E. Verin. 2012. “Oropharyngeal Dysphagia in Amyotrophic Lateral Sclerosis Alters Quality of Life”. Journal of Oral Rehabilitation. Wiley. doi:10.1111/joor.12019.
~7 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top